nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—CYP2E1—Fingolimod—multiple sclerosis	0.167	0.217	CbGbCtD
Metyrapone—ABCC3—Methotrexate—multiple sclerosis	0.112	0.145	CbGbCtD
Metyrapone—CYP2A6—Prednisolone—multiple sclerosis	0.105	0.136	CbGbCtD
Metyrapone—CYP2E1—Mitoxantrone—multiple sclerosis	0.0786	0.102	CbGbCtD
Metyrapone—CYP2A6—Dexamethasone—multiple sclerosis	0.0618	0.0801	CbGbCtD
Metyrapone—CYP3A4—Fingolimod—multiple sclerosis	0.0507	0.0657	CbGbCtD
Metyrapone—CYP2E1—Dexamethasone—multiple sclerosis	0.0408	0.0529	CbGbCtD
Metyrapone—CYP3A4—Methylprednisolone—multiple sclerosis	0.0327	0.0423	CbGbCtD
Metyrapone—CYP3A4—Triamcinolone—multiple sclerosis	0.0247	0.0321	CbGbCtD
Metyrapone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0238	0.0309	CbGbCtD
Metyrapone—CYP3A4—Betamethasone—multiple sclerosis	0.0212	0.0275	CbGbCtD
Metyrapone—CYP3A4—Prednisolone—multiple sclerosis	0.0209	0.0272	CbGbCtD
Metyrapone—CYP3A4—Prednisone—multiple sclerosis	0.0198	0.0257	CbGbCtD
Metyrapone—CYP3A4—Dexamethasone—multiple sclerosis	0.0123	0.016	CbGbCtD
Metyrapone—Adrenal insufficiency—Prednisone—multiple sclerosis	0.00518	0.0455	CcSEcCtD
Metyrapone—CYP11B2—Metabolism of steroid hormones and vitamin D—CYP27B1—multiple sclerosis	0.0045	0.0392	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of steroid hormones and vitamin D—CYP24A1—multiple sclerosis	0.0045	0.0392	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of steroid hormones and vitamin D—CYP27B1—multiple sclerosis	0.00388	0.0337	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of steroid hormones and vitamin D—CYP24A1—multiple sclerosis	0.00388	0.0337	CbGpPWpGaD
Metyrapone—White blood cell count decreased—Mitoxantrone—multiple sclerosis	0.00366	0.0321	CcSEcCtD
Metyrapone—Bone marrow depression—Azathioprine—multiple sclerosis	0.00334	0.0293	CcSEcCtD
Metyrapone—CYP11B2—Glucocorticoid biosynthesis—POMC—multiple sclerosis	0.00315	0.0274	CbGpPWpGaD
Metyrapone—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00279	0.0243	CbGpPWpGaD
Metyrapone—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00279	0.0243	CbGpPWpGaD
Metyrapone—CYP11B2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00275	0.024	CbGpPWpGaD
Metyrapone—CYP11B2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00275	0.024	CbGpPWpGaD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00273	0.0237	CbGpPWpGaD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00273	0.0237	CbGpPWpGaD
Metyrapone—CYP11B1—Glucocorticoid biosynthesis—POMC—multiple sclerosis	0.00271	0.0236	CbGpPWpGaD
Metyrapone—Bone marrow depression—Mitoxantrone—multiple sclerosis	0.0027	0.0237	CcSEcCtD
Metyrapone—Hirsutism—Prednisolone—multiple sclerosis	0.00257	0.0226	CcSEcCtD
Metyrapone—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00241	0.0209	CbGpPWpGaD
Metyrapone—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00241	0.0209	CbGpPWpGaD
Metyrapone—CYP11B1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00237	0.0206	CbGpPWpGaD
Metyrapone—CYP11B1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00237	0.0206	CbGpPWpGaD
Metyrapone—Hirsutism—Triamcinolone—multiple sclerosis	0.00236	0.0208	CcSEcCtD
Metyrapone—Hirsutism—Methylprednisolone—multiple sclerosis	0.00236	0.0207	CcSEcCtD
Metyrapone—CYP11B2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00226	0.0197	CbGpPWpGaD
Metyrapone—CYP11B2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00226	0.0197	CbGpPWpGaD
Metyrapone—Angiopathy—Fingolimod—multiple sclerosis	0.00223	0.0196	CcSEcCtD
Metyrapone—Alopecia—Fingolimod—multiple sclerosis	0.00217	0.019	CcSEcCtD
Metyrapone—Hirsutism—Dexamethasone—multiple sclerosis	0.00215	0.0188	CcSEcCtD
Metyrapone—Hirsutism—Betamethasone—multiple sclerosis	0.00215	0.0188	CcSEcCtD
Metyrapone—ABCC3—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00212	0.0184	CbGpPWpGaD
Metyrapone—Dermatitis atopic—Prednisolone—multiple sclerosis	0.00202	0.0177	CcSEcCtD
Metyrapone—CYP11B1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00195	0.017	CbGpPWpGaD
Metyrapone—CYP11B1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00195	0.017	CbGpPWpGaD
Metyrapone—Hirsutism—Prednisone—multiple sclerosis	0.00187	0.0164	CcSEcCtD
Metyrapone—Dermatitis atopic—Triamcinolone—multiple sclerosis	0.00186	0.0163	CcSEcCtD
Metyrapone—Hypertension—Fingolimod—multiple sclerosis	0.00184	0.0162	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00181	0.0159	CcSEcCtD
Metyrapone—Nervous system disorder—Fingolimod—multiple sclerosis	0.00171	0.015	CcSEcCtD
Metyrapone—Skin disorder—Fingolimod—multiple sclerosis	0.00169	0.0149	CcSEcCtD
Metyrapone—Abdominal discomfort—Cladribine—multiple sclerosis	0.00167	0.0146	CcSEcCtD
Metyrapone—Pancytopenia—Cladribine—multiple sclerosis	0.00165	0.0145	CcSEcCtD
Metyrapone—Hypotension—Fingolimod—multiple sclerosis	0.00163	0.0143	CcSEcCtD
Metyrapone—ABCC3—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00155	0.0135	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00151	0.0132	CcSEcCtD
Metyrapone—Dermatitis atopic—Prednisone—multiple sclerosis	0.00147	0.0129	CcSEcCtD
Metyrapone—Abdominal discomfort—Azathioprine—multiple sclerosis	0.00136	0.0119	CcSEcCtD
Metyrapone—CYP11B2—Endogenous sterols—POMC—multiple sclerosis	0.00135	0.0118	CbGpPWpGaD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00135	0.0117	CbGpPWpGaD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00135	0.0117	CbGpPWpGaD
Metyrapone—Bone marrow depression—Methotrexate—multiple sclerosis	0.00134	0.0118	CcSEcCtD
Metyrapone—Pancytopenia—Azathioprine—multiple sclerosis	0.00134	0.0118	CcSEcCtD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00133	0.0115	CbGpPWpGaD
Metyrapone—Endocrine disorder—Prednisone—multiple sclerosis	0.00131	0.0115	CcSEcCtD
Metyrapone—Angiopathy—Cladribine—multiple sclerosis	0.00126	0.0111	CcSEcCtD
Metyrapone—Alopecia—Cladribine—multiple sclerosis	0.00123	0.0108	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—CYP27B1—multiple sclerosis	0.0012	0.0105	CbGpPWpGaD
Metyrapone—CYP11B2—Biological oxidations—CYP24A1—multiple sclerosis	0.0012	0.0105	CbGpPWpGaD
Metyrapone—CYP11B2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00119	0.0103	CbGpPWpGaD
Metyrapone—CYP11B2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00119	0.0103	CbGpPWpGaD
Metyrapone—CYP11B1—Endogenous sterols—POMC—multiple sclerosis	0.00117	0.0101	CbGpPWpGaD
Metyrapone—Dizziness—Fingolimod—multiple sclerosis	0.00115	0.0101	CcSEcCtD
Metyrapone—Headache—Fingolimod—multiple sclerosis	0.00109	0.00959	CcSEcCtD
Metyrapone—Pancytopenia—Mitoxantrone—multiple sclerosis	0.00109	0.00953	CcSEcCtD
Metyrapone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00108	0.00944	CbGpPWpGaD
Metyrapone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00108	0.00944	CbGpPWpGaD
Metyrapone—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00107	0.00931	CbGpPWpGaD
Metyrapone—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00107	0.00931	CbGpPWpGaD
Metyrapone—CYP11B1—Biological oxidations—CYP24A1—multiple sclerosis	0.00104	0.00901	CbGpPWpGaD
Metyrapone—CYP11B1—Biological oxidations—CYP27B1—multiple sclerosis	0.00104	0.00901	CbGpPWpGaD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00102	0.00899	CcSEcCtD
Metyrapone—ABCC3—Recycling of bile acids and salts—ALB—multiple sclerosis	0.00102	0.00889	CbGpPWpGaD
Metyrapone—CYP11B1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00102	0.00888	CbGpPWpGaD
Metyrapone—CYP11B1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00102	0.00888	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.00101	0.00881	CbGpPWpGaD
Metyrapone—Alopecia—Azathioprine—multiple sclerosis	0.001	0.00878	CcSEcCtD
Metyrapone—CYP11B2—ACE Inhibitor Pathway—TGFB1—multiple sclerosis	0.000993	0.00864	CbGpPWpGaD
Metyrapone—Nervous system disorder—Cladribine—multiple sclerosis	0.000969	0.00851	CcSEcCtD
Metyrapone—Skin disorder—Cladribine—multiple sclerosis	0.00096	0.00843	CcSEcCtD
Metyrapone—Hypotension—Cladribine—multiple sclerosis	0.000924	0.00811	CcSEcCtD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000893	0.00776	CbGpPWpGaD
Metyrapone—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00088	0.00765	CbGpPWpGaD
Metyrapone—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00088	0.00765	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.000873	0.00759	CbGpPWpGaD
Metyrapone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000857	0.00746	CbGpPWpGaD
Metyrapone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000857	0.00746	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000853	0.00749	CcSEcCtD
Metyrapone—CYP2E1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000846	0.00736	CbGpPWpGaD
Metyrapone—CYP2E1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000846	0.00736	CbGpPWpGaD
Metyrapone—Pain—Cladribine—multiple sclerosis	0.000845	0.00742	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000833	0.00731	CcSEcCtD
Metyrapone—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000808	0.0071	CcSEcCtD
Metyrapone—Alopecia—Mitoxantrone—multiple sclerosis	0.000808	0.0071	CcSEcCtD
Metyrapone—Abdominal pain—Cladribine—multiple sclerosis	0.000782	0.00686	CcSEcCtD
Metyrapone—Skin disorder—Azathioprine—multiple sclerosis	0.000781	0.00686	CcSEcCtD
Metyrapone—Hypotension—Azathioprine—multiple sclerosis	0.000751	0.0066	CcSEcCtD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000695	0.00605	CbGpPWpGaD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000695	0.00605	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000694	0.00609	CcSEcCtD
Metyrapone—Hypertension—Mitoxantrone—multiple sclerosis	0.000687	0.00604	CcSEcCtD
Metyrapone—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000657	0.00577	CcSEcCtD
Metyrapone—Dizziness—Cladribine—multiple sclerosis	0.000654	0.00574	CcSEcCtD
Metyrapone—Abdominal pain—Azathioprine—multiple sclerosis	0.000635	0.00558	CcSEcCtD
Metyrapone—Skin disorder—Mitoxantrone—multiple sclerosis	0.000631	0.00554	CcSEcCtD
Metyrapone—Vomiting—Cladribine—multiple sclerosis	0.000629	0.00552	CcSEcCtD
Metyrapone—CYP11B2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000628	0.00546	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000627	0.00545	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000627	0.00545	CbGpPWpGaD
Metyrapone—Angiopathy—Methylprednisolone—multiple sclerosis	0.000625	0.00548	CcSEcCtD
Metyrapone—Headache—Cladribine—multiple sclerosis	0.000619	0.00544	CcSEcCtD
Metyrapone—Hypotension—Mitoxantrone—multiple sclerosis	0.000607	0.00533	CcSEcCtD
Metyrapone—Nausea—Cladribine—multiple sclerosis	0.000587	0.00516	CcSEcCtD
Metyrapone—Angiopathy—Betamethasone—multiple sclerosis	0.000568	0.00499	CcSEcCtD
Metyrapone—Angiopathy—Dexamethasone—multiple sclerosis	0.000568	0.00499	CcSEcCtD
Metyrapone—Hypertension—Prednisolone—multiple sclerosis	0.000564	0.00495	CcSEcCtD
Metyrapone—Pain—Mitoxantrone—multiple sclerosis	0.000556	0.00488	CcSEcCtD
Metyrapone—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000555	0.00482	CbGpPWpGaD
Metyrapone—Alopecia—Dexamethasone—multiple sclerosis	0.000553	0.00486	CcSEcCtD
Metyrapone—Alopecia—Betamethasone—multiple sclerosis	0.000553	0.00486	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000546	0.00479	CcSEcCtD
Metyrapone—CYP11B1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000541	0.00471	CbGpPWpGaD
Metyrapone—Pancytopenia—Methotrexate—multiple sclerosis	0.000541	0.00475	CcSEcCtD
Metyrapone—ABCC3—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000535	0.00465	CbGpPWpGaD
Metyrapone—Dizziness—Azathioprine—multiple sclerosis	0.000532	0.00467	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000531	0.00467	CcSEcCtD
Metyrapone—Hypertension—Triamcinolone—multiple sclerosis	0.000519	0.00455	CcSEcCtD
Metyrapone—Hypertension—Methylprednisolone—multiple sclerosis	0.000517	0.00454	CcSEcCtD
Metyrapone—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000514	0.00451	CcSEcCtD
Metyrapone—Vomiting—Azathioprine—multiple sclerosis	0.000511	0.00449	CcSEcCtD
Metyrapone—CYP11B2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000509	0.00443	CbGpPWpGaD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000507	0.00445	CcSEcCtD
Metyrapone—Headache—Azathioprine—multiple sclerosis	0.000504	0.00442	CcSEcCtD
Metyrapone—Angiopathy—Prednisone—multiple sclerosis	0.000495	0.00434	CcSEcCtD
Metyrapone—Alopecia—Prednisone—multiple sclerosis	0.000482	0.00423	CcSEcCtD
Metyrapone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00048	0.00421	CcSEcCtD
Metyrapone—Nausea—Azathioprine—multiple sclerosis	0.000477	0.00419	CcSEcCtD
Metyrapone—Skin disorder—Methylprednisolone—multiple sclerosis	0.000475	0.00417	CcSEcCtD
Metyrapone—Hypertension—Betamethasone—multiple sclerosis	0.000471	0.00413	CcSEcCtD
Metyrapone—Hypertension—Dexamethasone—multiple sclerosis	0.000471	0.00413	CcSEcCtD
Metyrapone—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000467	0.00406	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000467	0.00406	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000462	0.00401	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000462	0.00401	CbGpPWpGaD
Metyrapone—Hypotension—Methylprednisolone—multiple sclerosis	0.000457	0.00401	CcSEcCtD
Metyrapone—Pain—Prednisolone—multiple sclerosis	0.000456	0.004	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000442	0.00384	CbGpPWpGaD
Metyrapone—CYP11B1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000439	0.00381	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—TLR4—multiple sclerosis	0.000438	0.00381	CbGpPWpGaD
Metyrapone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000436	0.00383	CcSEcCtD
Metyrapone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000436	0.00383	CcSEcCtD
Metyrapone—Pain—Triamcinolone—multiple sclerosis	0.000419	0.00368	CcSEcCtD
Metyrapone—Hypotension—Dexamethasone—multiple sclerosis	0.000416	0.00365	CcSEcCtD
Metyrapone—Hypotension—Betamethasone—multiple sclerosis	0.000416	0.00365	CcSEcCtD
Metyrapone—Angiopathy—Methotrexate—multiple sclerosis	0.000413	0.00363	CcSEcCtD
Metyrapone—Vomiting—Mitoxantrone—multiple sclerosis	0.000413	0.00363	CcSEcCtD
Metyrapone—Hypertension—Prednisone—multiple sclerosis	0.00041	0.0036	CcSEcCtD
Metyrapone—Headache—Mitoxantrone—multiple sclerosis	0.000407	0.00357	CcSEcCtD
Metyrapone—Alopecia—Methotrexate—multiple sclerosis	0.000403	0.00354	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000401	0.00352	CcSEcCtD
Metyrapone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.0004	0.00351	CcSEcCtD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000398	0.00346	CbGpPWpGaD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000398	0.00346	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000398	0.00346	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000398	0.00346	CbGpPWpGaD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000393	0.00341	CbGpPWpGaD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000393	0.00341	CbGpPWpGaD
Metyrapone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000387	0.0034	CcSEcCtD
Metyrapone—Nausea—Mitoxantrone—multiple sclerosis	0.000386	0.00339	CcSEcCtD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—POMC—multiple sclerosis	0.000384	0.00334	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000384	0.00337	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000384	0.00337	CcSEcCtD
Metyrapone—Pain—Betamethasone—multiple sclerosis	0.00038	0.00334	CcSEcCtD
Metyrapone—Pain—Dexamethasone—multiple sclerosis	0.00038	0.00334	CcSEcCtD
Metyrapone—Nervous system disorder—Prednisone—multiple sclerosis	0.00038	0.00334	CcSEcCtD
Metyrapone—Skin disorder—Prednisone—multiple sclerosis	0.000376	0.0033	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—CYP27B1—multiple sclerosis	0.000369	0.00321	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—CYP24A1—multiple sclerosis	0.000369	0.00321	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000364	0.00317	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000364	0.00317	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000364	0.00319	CcSEcCtD
Metyrapone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000364	0.00319	CcSEcCtD
Metyrapone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000357	0.0031	CbGpPWpGaD
Metyrapone—Dizziness—Prednisolone—multiple sclerosis	0.000353	0.0031	CcSEcCtD
Metyrapone—Abdominal pain—Betamethasone—multiple sclerosis	0.000352	0.00309	CcSEcCtD
Metyrapone—Abdominal pain—Dexamethasone—multiple sclerosis	0.000352	0.00309	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000335	0.00294	CcSEcCtD
Metyrapone—Headache—Prednisolone—multiple sclerosis	0.000334	0.00293	CcSEcCtD
Metyrapone—Dizziness—Triamcinolone—multiple sclerosis	0.000324	0.00285	CcSEcCtD
Metyrapone—Dizziness—Methylprednisolone—multiple sclerosis	0.000323	0.00284	CcSEcCtD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000322	0.0028	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000322	0.0028	CbGpPWpGaD
Metyrapone—Nervous system disorder—Methotrexate—multiple sclerosis	0.000317	0.00279	CcSEcCtD
Metyrapone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000317	0.00278	CcSEcCtD
Metyrapone—Nausea—Prednisolone—multiple sclerosis	0.000317	0.00278	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—multiple sclerosis	0.000314	0.00276	CcSEcCtD
Metyrapone—Vomiting—Triamcinolone—multiple sclerosis	0.000312	0.00274	CcSEcCtD
Metyrapone—Vomiting—Methylprednisolone—multiple sclerosis	0.000311	0.00273	CcSEcCtD
Metyrapone—Headache—Triamcinolone—multiple sclerosis	0.000307	0.0027	CcSEcCtD
Metyrapone—Headache—Methylprednisolone—multiple sclerosis	0.000306	0.00269	CcSEcCtD
Metyrapone—Abdominal pain—Prednisone—multiple sclerosis	0.000306	0.00269	CcSEcCtD
Metyrapone—Hypotension—Methotrexate—multiple sclerosis	0.000303	0.00266	CcSEcCtD
Metyrapone—Dizziness—Betamethasone—multiple sclerosis	0.000294	0.00258	CcSEcCtD
Metyrapone—Dizziness—Dexamethasone—multiple sclerosis	0.000294	0.00258	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000293	0.00255	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—SRM—multiple sclerosis	0.000292	0.00254	CbGpPWpGaD
Metyrapone—Nausea—Triamcinolone—multiple sclerosis	0.000291	0.00256	CcSEcCtD
Metyrapone—Nausea—Methylprednisolone—multiple sclerosis	0.000291	0.00255	CcSEcCtD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000286	0.00249	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000286	0.00249	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—IL2—multiple sclerosis	0.000284	0.00247	CbGpPWpGaD
Metyrapone—Vomiting—Betamethasone—multiple sclerosis	0.000283	0.00248	CcSEcCtD
Metyrapone—Vomiting—Dexamethasone—multiple sclerosis	0.000283	0.00248	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00028	0.00245	CcSEcCtD
Metyrapone—Headache—Dexamethasone—multiple sclerosis	0.000279	0.00245	CcSEcCtD
Metyrapone—Headache—Betamethasone—multiple sclerosis	0.000279	0.00245	CcSEcCtD
Metyrapone—Pain—Methotrexate—multiple sclerosis	0.000277	0.00243	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—POMC—multiple sclerosis	0.00027	0.00235	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000265	0.00232	CcSEcCtD
Metyrapone—Nausea—Betamethasone—multiple sclerosis	0.000264	0.00232	CcSEcCtD
Metyrapone—Nausea—Dexamethasone—multiple sclerosis	0.000264	0.00232	CcSEcCtD
Metyrapone—Dizziness—Prednisone—multiple sclerosis	0.000256	0.00225	CcSEcCtD
Metyrapone—Abdominal pain—Methotrexate—multiple sclerosis	0.000256	0.00225	CcSEcCtD
Metyrapone—CYP11B1—Metabolism—SRM—multiple sclerosis	0.000251	0.00219	CbGpPWpGaD
Metyrapone—Vomiting—Prednisone—multiple sclerosis	0.000246	0.00216	CcSEcCtD
Metyrapone—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000244	0.00212	CbGpPWpGaD
Metyrapone—Headache—Prednisone—multiple sclerosis	0.000243	0.00213	CcSEcCtD
Metyrapone—CYP11B1—Biological oxidations—POMC—multiple sclerosis	0.000233	0.00203	CbGpPWpGaD
Metyrapone—Nausea—Prednisone—multiple sclerosis	0.00023	0.00202	CcSEcCtD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000222	0.00193	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—TGFB1—multiple sclerosis	0.000222	0.00193	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—MAPK1—multiple sclerosis	0.000217	0.00189	CbGpPWpGaD
Metyrapone—Dizziness—Methotrexate—multiple sclerosis	0.000214	0.00188	CcSEcCtD
Metyrapone—Vomiting—Methotrexate—multiple sclerosis	0.000206	0.00181	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—CYP24A1—multiple sclerosis	0.000206	0.00179	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CYP27B1—multiple sclerosis	0.000206	0.00179	CbGpPWpGaD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000205	0.00178	CbGpPWpGaD
Metyrapone—Headache—Methotrexate—multiple sclerosis	0.000203	0.00178	CcSEcCtD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000201	0.00175	CbGpPWpGaD
Metyrapone—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000198	0.00172	CbGpPWpGaD
Metyrapone—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000193	0.00168	CbGpPWpGaD
Metyrapone—Nausea—Methotrexate—multiple sclerosis	0.000192	0.00169	CcSEcCtD
Metyrapone—CYP11B2—Metabolism—GPC5—multiple sclerosis	0.000188	0.00164	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SRM—multiple sclerosis	0.000181	0.00157	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CYP24A1—multiple sclerosis	0.000177	0.00154	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CYP27B1—multiple sclerosis	0.000177	0.00154	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000175	0.00153	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000173	0.00151	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000171	0.00149	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000171	0.00149	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000169	0.00147	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000169	0.00147	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GPC5—multiple sclerosis	0.000162	0.00141	CbGpPWpGaD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000156	0.00136	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—RRM1—multiple sclerosis	0.000156	0.00135	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000155	0.00135	CbGpPWpGaD
Metyrapone—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	0.000142	0.00124	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—RRM1—multiple sclerosis	0.000134	0.00117	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP27B1—multiple sclerosis	0.000128	0.00111	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP24A1—multiple sclerosis	0.000128	0.00111	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000125	0.00108	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000121	0.00105	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GPC5—multiple sclerosis	0.000117	0.00101	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SRM—multiple sclerosis	0.000113	0.000986	CbGpPWpGaD
Metyrapone—ABCC3—NRF2 pathway—TGFB1—multiple sclerosis	0.00011	0.000959	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—POMC—multiple sclerosis	0.000105	0.000914	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000104	0.000906	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000104	0.000903	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—RRM1—multiple sclerosis	9.67e-05	0.000841	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.47e-05	0.000823	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SRM—multiple sclerosis	8.96e-05	0.000779	CbGpPWpGaD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.95e-05	0.000778	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.95e-05	0.000778	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—BCHE—multiple sclerosis	8.95e-05	0.000778	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—POMC—multiple sclerosis	8.31e-05	0.000722	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.16e-05	0.000709	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	7.99e-05	0.000695	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	7.99e-05	0.000695	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—BCHE—multiple sclerosis	7.71e-05	0.000671	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.5e-05	0.000652	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GPC5—multiple sclerosis	7.31e-05	0.000636	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.25e-05	0.000631	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	6.91e-05	0.000601	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.44e-05	0.00056	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	6.31e-05	0.000549	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	6.31e-05	0.000549	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—RRM1—multiple sclerosis	6.06e-05	0.000527	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.87e-05	0.000511	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPC5—multiple sclerosis	5.77e-05	0.000502	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.59e-05	0.000486	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—BCHE—multiple sclerosis	5.55e-05	0.000483	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—APOE—multiple sclerosis	5.38e-05	0.000468	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—RRM1—multiple sclerosis	4.79e-05	0.000416	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—APOE—multiple sclerosis	4.64e-05	0.000403	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—POMC—multiple sclerosis	4.62e-05	0.000402	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ALB—multiple sclerosis	4.22e-05	0.000367	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SRM—multiple sclerosis	4.16e-05	0.000362	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—POMC—multiple sclerosis	3.98e-05	0.000347	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.85e-05	0.000335	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ALB—multiple sclerosis	3.63e-05	0.000316	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—BCHE—multiple sclerosis	3.48e-05	0.000302	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—APOE—multiple sclerosis	3.34e-05	0.00029	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.93e-05	0.000255	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.93e-05	0.000255	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—POMC—multiple sclerosis	2.87e-05	0.00025	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—BCHE—multiple sclerosis	2.75e-05	0.000239	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.68e-05	0.000233	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ALB—multiple sclerosis	2.62e-05	0.000228	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.22e-05	0.000193	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—APOE—multiple sclerosis	2.09e-05	0.000182	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—POMC—multiple sclerosis	1.8e-05	0.000156	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—APOE—multiple sclerosis	1.65e-05	0.000144	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ALB—multiple sclerosis	1.64e-05	0.000143	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—POMC—multiple sclerosis	1.42e-05	0.000124	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ALB—multiple sclerosis	1.29e-05	0.000113	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.28e-05	0.000111	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—APOE—multiple sclerosis	7.67e-06	6.67e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—POMC—multiple sclerosis	6.59e-06	5.73e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALB—multiple sclerosis	6.01e-06	5.23e-05	CbGpPWpGaD
